Novo Nordisk (NVO) Plunges 16% After Obesity Drug Misses Against Lilly
NVO (Novo Nordisk’s U.S. ADR) dropped over 16% today because its new obesity drug CagriSema produced weaker weight‑loss results than Eli Lilly’s rival drug tirzepatide in a key late‑stage trial, raising fears that Novo will be less competitive in the next generation of weight‑loss medicines.
What happened today
-
Novo Nordisk reported Phase 3 data showing that CagriSema led to less weight loss over about 84 weeks than tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound.
-
Because this was a head‑to‑head style comparison, the drug failed to achieve its main goal of being at least “non‑inferior” to tirzepatide, which is what investors had hoped for.
-
After the announcement, NVO ADRs fell more than 14–16% in U.S. trading, with the Copenhagen shares likewise dropping over 15% and hitting their lowest levels since mid‑2021.
Why the market reacted so hard
-
CagriSema is Novo’s next‑generation obesity therapy and was expected to help it defend and extend its lead created by Wegovy and Ozempic; underperforming Lilly’s drug suggests Lilly may dominate future market share and pricing power in obesity drugs.
-
The stock was already under pressure earlier this month after Novo guided to a 5–13% decline in 2026 sales because of U.S. price cuts, patent expiries, and tougher competition, so today’s trial setback compounds an existing negative narrative.
-
The combined effect has erased much of the valuation built up in the “Wegovy era,” with hundreds of billions of dollars in market cap lost from the 2024 peak and shares now roughly back to pre‑Wegovy levels.
Key takeaway for investors
-
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
Tickeron AI Perspective
NVO's RSI Oscillator ascends from oversold territory
The RSI Oscillator for NVO moved out of oversold territory on March 05, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In of the 22 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on March 09, 2026. You may want to consider a long position or call options on NVO as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for NVO just turned positive on March 09, 2026. Looking at past instances where NVO's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVO advanced for three days, in of 334 cases, the price rose further within the following month. The odds of a continued upward trend are .
NVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
NVO moved below its 50-day moving average on February 03, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NVO crossed bearishly below the 50-day moving average on February 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for NVO entered a downward trend on March 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.705) is normal, around the industry mean (9.325). P/E Ratio (10.904) is within average values for comparable stocks, (22.496). Projected Growth (PEG Ratio) (4.718) is also within normal values, averaging (2.279). NVO has a moderately high Dividend Yield (0.045) as compared to the industry average of (0.025). P/S Ratio (3.584) is also within normal values, averaging (3.956).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement